RBC Capital on Karyopharm Therapeutics (KPTI): 'See Buying Oppty On Weakness'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $16.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
